Search

Displaying results 5191 - 5200 of 5365 in total
  1. Drug

    Nivolumab

    go.drugbank.com/drugs/DB09035
    ApprovedInvestigational

    Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for addition...

  2. Drug

    Etrolizumab

    go.drugbank.com/drugs/DB12189
    Investigational

    [A244564, A244584] Etrolizumab is a humanized IgG1κ monoclonal antibody directed against the β7 subunit of gastrointestinal α4β7 and αEβ7 integrins that, due to its target specificity, appears as or more

  3. Drug

    Estradiol acetate

    go.drugbank.com/drugs/DB13952
    ApprovedVet approved

    Estradiol acetate is commercially available as Femring, a vaginal ring used for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy due to menopause.

  4. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    Coagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen.

  5. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments

  6. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries.

  7. Drug

    Xylazine

    go.drugbank.com/drugs/DB11477
    InvestigationalVet approved

    [L42680] The intentional and unintentional use of xylazine is a cause for concern due to its side effects.

  8. Drug

    Apalutamide

    go.drugbank.com/drugs/DB11901
    ApprovedInvestigational

    Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death [A31846].

  9. Drug

    Atorvastatin

    go.drugbank.com/drugs/DB01076
    ApprovedInvestigational

    [A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996.

  10. Drug

    Barbexaclone

    go.drugbank.com/drugs/DB09001
    Experimental

    There has been a case of barbexaclone abuse due to the amphetamine like properties of propylhexedrine, although the comparative abuse potential is much lower than amphetamine.